Mizuho Lowers Upstream Bio (NASDAQ:UPB) Price Target to $50.00

Upstream Bio (NASDAQ:UPB) had its target price lowered by equities researchers at Mizuho from $51.00 to $50.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 450.06% from the stock’s previous close.

A number of other research firms have also commented on UPB. Weiss Ratings lowered shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Evercore lowered shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective for the company. in a research note on Friday, March 27th. Finally, Wall Street Zen lowered shares of Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Upstream Bio presently has a consensus rating of “Hold” and an average price target of $38.75.

Upstream Bio Price Performance

NASDAQ UPB opened at $9.09 on Thursday. Upstream Bio has a 12 month low of $7.25 and a 12 month high of $33.68. The firm has a market capitalization of $494.68 million, a PE ratio of -3.12 and a beta of 1.28. The company’s 50 day simple moving average is $9.26 and its 200 day simple moving average is $19.20.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.02). The business had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. Sell-side analysts anticipate that Upstream Bio will post -3.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Entropy Technologies LP bought a new position in Upstream Bio in the 1st quarter worth $210,000. Renaissance Technologies LLC raised its holdings in Upstream Bio by 278.7% in the 1st quarter. Renaissance Technologies LLC now owns 62,100 shares of the company’s stock worth $559,000 after acquiring an additional 45,700 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in Upstream Bio in the 1st quarter worth $1,666,000. Dimensional Fund Advisors LP bought a new position in Upstream Bio in the 1st quarter worth $719,000. Finally, SEB Asset Management AB bought a new position in Upstream Bio in the 1st quarter worth $7,906,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.